![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Recently, neuroinflammation and the immune-kynurenine pathway have received increased attention in the psychoimmunology field of major depressive disorder (MDD), while studies related to anxiety disorders have been very limited.
Objective: This study reviewed possible mechanisms by which stress or inflammation modulate anxiety through tryptophan metabolism and the kynurenine pathway.
Methods: Relevant literature was identified through a search of MEDLINE via PubMed.
Results: Accumulating evidence has indicated the modulatory effects of the immune-kynurenine pathway on anxiety. The tryptophan catabolites (TRYCATs) in the kynurenine pathway imbalanced by stress or inflammation induce serotonin and melatonin deficiency, making anxiety reactions more sensitive. In addition, TRYCATs cause or sustain anxiety by acting as endogenous anxiogens or anxiolytics, an NMDA agonist or antagonist, or a free radical generator.
Conclusion: We hope that our understanding of the psychoimmunological mechanisms of anxiety will be expanded and anxiety-related studies will receive greater attention.
Keywords: Anxiety, kynurenine, tryptophan catabolites, serotonin, psychoimmunology, neuroinflammation.
Current Neuropharmacology
Title:Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders
Volume: 16 Issue: 5
Author(s): Yong-Ku Kim and Sang Won Jeon*
Affiliation:
- Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul,Korea
Keywords: Anxiety, kynurenine, tryptophan catabolites, serotonin, psychoimmunology, neuroinflammation.
Abstract: Background: Recently, neuroinflammation and the immune-kynurenine pathway have received increased attention in the psychoimmunology field of major depressive disorder (MDD), while studies related to anxiety disorders have been very limited.
Objective: This study reviewed possible mechanisms by which stress or inflammation modulate anxiety through tryptophan metabolism and the kynurenine pathway.
Methods: Relevant literature was identified through a search of MEDLINE via PubMed.
Results: Accumulating evidence has indicated the modulatory effects of the immune-kynurenine pathway on anxiety. The tryptophan catabolites (TRYCATs) in the kynurenine pathway imbalanced by stress or inflammation induce serotonin and melatonin deficiency, making anxiety reactions more sensitive. In addition, TRYCATs cause or sustain anxiety by acting as endogenous anxiogens or anxiolytics, an NMDA agonist or antagonist, or a free radical generator.
Conclusion: We hope that our understanding of the psychoimmunological mechanisms of anxiety will be expanded and anxiety-related studies will receive greater attention.
Export Options
About this article
Cite this article as:
Kim Yong-Ku and Jeon Won Sang *, Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders, Current Neuropharmacology 2018; 16 (5) . https://dx.doi.org/10.2174/1570159X15666170913110426
DOI https://dx.doi.org/10.2174/1570159X15666170913110426 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Extracorporeal Lung Assist for Sepsis and Acute Respiratory Distress Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Autism, Mitochondria and Polybrominated Diphenyl Ether Exposure
CNS & Neurological Disorders - Drug Targets Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets MR Spectroscopy Findings of the Basal Ganglia in Bipolar Disorders: a Systematic Review
Current Psychiatry Reviews Histamine as an Anticonvulsant Inhibitory Neurotransmitter
Current Neuropharmacology Microvascular Alterations in Hypertension and Vascular Aging
Current Hypertension Reviews Psychotherapy, Suicide and Depression, Body Dysmorphic Disorder, Aggression, an Unusual Case, and the Case for Harm Reduction in Treating Adolescent Substance Abuse
Adolescent Psychiatry MiR-125a-5p Alleviates Dysfunction and Inflammation of Pentylenetetrazol- induced Epilepsy Through Targeting Calmodulin-dependent Protein Kinase IV (CAMK4)
Current Neurovascular Research The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Uterine Function: From Normal to Polycystic Ovarian Syndrome Alterations
Current Medicinal Chemistry Social Cognition Deficit in Schizophrenia: Accounting for Pragmatic Deficits in Communication Abilities?
Current Psychiatry Reviews Oxidative Stress and Drugs of Abuse: An Update
Mini-Reviews in Organic Chemistry Electrochemical Biosensors for the Determination of the Antioxidant Capacity in Foods and Beverages Based on Reactive Oxygen Species
Current Analytical Chemistry Phytoconstituents and their Possible Mechanistic Profile for Alzheimer’s Disease – A Literature Review
Current Drug Targets Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Human Amylin: From Pathology to Physiology and Pharmacology
Current Protein & Peptide Science T Allele of the <i>DRD2 Taq1</i>A Gene Polymorphism Increases the Predisposition to Drug Addiction in Indonesian Population
Current Pharmacogenomics and Personalized Medicine Serum Biomarkers for Noninvasive Diagnosis of Liver Diseases: How Laudable are These Tools?
Current Chemical Biology The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets Errors in ADAS-Cog Administration and Scoring May Undermine Clinical Trials Results
Current Alzheimer Research